The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance

This landmark study by Lee, Zeng, Drew, and colleagues, published in Cell Metabolism, was one of the first to identify and characterize MOTS-c as a mitochondrial-derived peptide with powerful metabolic regulatory properties. It laid the scientific foundation for all subsequent MOTS-c research.

The researchers discovered that MOTS-c is encoded within the mitochondrial genome and functions as a circulating signaling molecule. They tested its metabolic effects in both cell culture and animal models, including mice fed a high-fat diet designed to induce obesity and insulin resistance.

The results were remarkable: MOTS-c treatment promoted metabolic homeostasis, significantly reduced obesity, and reversed insulin resistance. The peptide activated AMPK, a master metabolic switch that mimics many of the beneficial effects of exercise. Treated animals showed improved glucose tolerance, reduced fat accumulation, and enhanced overall metabolic function even while consuming a high-fat diet.

This foundational study established MOTS-c as a major discovery in metabolic science. By demonstrating that a naturally occurring mitochondrial peptide could so powerfully influence whole-body metabolism, the research opened an entirely new avenue for addressing obesity and metabolic disease. MOTS-c's ability to activate exercise-like metabolic pathways has earned it the designation of an exercise mimetic peptide, offering hope for those who struggle with metabolic dysfunction.